Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
University of British Columbia
$25,000.00
A disease-modifying role for the microbiome in Parkinson's disease: from clinical progression to intervention
FY 2018-19
Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder and predicted to grow exponentially in the next few decades. The causes of PD are largely unknown and there is currently no cure or disease-modifying therapy available. Recently, converging evidence from various fields is suggesting that PD might start in the gut. Central to this theme are chronic constipation preceding motoric deficits seen in PD, changes in the microbiome composition of the gut, leakiness of the gut and evidence of inflammation with subsequent spread of the disease process from the gut to the brain. Much remains to be learned about the different factors and their interplay, though, to develop targeted therapies.
Our team proposes to study two major aims: 1) To examine the detailed composition of the gut microbiome as well as associated gut inflammation and barrier function and to analyze how changes correlate with the presence of PD, symptoms and with progression in a large cohort of patients vs. control subjects. 2) To examine and influence those mechanisms in different genetic mouse models of PD with the ability to link changes in stool content from human donors to tissue changes in mice, inflammation and lipids and how they affect nerve cell health.
We will assemble the so far largest cohort of patients with PD for studies of the gut microbiome and will use highly sensitive methods for superior resolution at the species level of intestinal organisms. We will follow patients over five years and compare them to unaffected spouses and siblings. This study is unique in the comprehensive usage of different markers to explore gut function and the microbiome.
Our interdisciplinary, pan-Canadian research team combines expertise in clinical care, microbiology, genetics, immunology and animal models. Discoveries generated through this work could lead to insights into the mechanisms that initiate and propagate PD, to identification of biomarkers and to much-needed therapies.
Department
Program
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
399003
Name
Appel-Cresswell Silke
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
A disease-modifying role for the microbiome in Parkinson's disease: from clinical progression to intervention
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Alpha-Synuclein; Animal Studies; Faecal Transfer; Host Genetics; Human Cohorts; Inflammation; Lipidomics; Microbiome; Parkinson'S Disease; Sex
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder and predicted to grow exponentially in the next few decades. The causes of PD are largely unknown and there is currently no cure or disease-modifying therapy available. Recently, converging evidence from various fields is suggesting that PD might start in the gut. Central to this theme are chronic constipation preceding motoric deficits seen in PD, changes in the microbiome composition of the gut, leakiness of the gut and evidence of inflammation with subsequent spread of the disease process from the gut to the brain. Much remains to be learned about the different factors and their interplay, though, to develop targeted therapies.
Our team proposes to study two major aims: 1) To examine the detailed composition of the gut microbiome as well as associated gut inflammation and barrier function and to analyze how changes correlate with the presence of PD, symptoms and with progression in a large cohort of patients vs. control subjects. 2) To examine and influence those mechanisms in different genetic mouse models of PD with the ability to link changes in stool content from human donors to tissue changes in mice, inflammation and lipids and how they affect nerve cell health.
We will assemble the so far largest cohort of patients with PD for studies of the gut microbiome and will use highly sensitive methods for superior resolution at the species level of intestinal organisms. We will follow patients over five years and compare them to unaffected spouses and siblings. This study is unique in the comprehensive usage of different markers to explore gut function and the microbiome.
Our interdisciplinary, pan-Canadian research team combines expertise in clinical care, microbiology, genetics, immunology and animal models. Discoveries generated through this work could lead to insights into the mechanisms that initiate and propagate PD, to identification of biomarkers and to much-needed therapies.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Appel-Cresswell, Silke; Finlay, Barton B; Martino, Davide; Rousseaux, Maxime W; Schlossmacher, Michael G
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $25,000~ $0~